WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004005461) ANTISENSE MODULATION OF INSULIN-LIKE GROWTH FACTOR 2 EXPRESSION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/005461    International Application No.:    PCT/US2003/020309
Publication Date: 15.01.2004 International Filing Date: 25.06.2003
Chapter 2 Demand Filed:    02.02.2004    
IPC:
A61K 38/00 (2006.01), C07H 21/04 (2006.01), C12N 15/11 (2006.01)
Applicants: ISIS PHARMACEUTICALS, INC. [US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US) (For All Designated States Except US).
BHANOT, Sanjay [CA/US]; (US) (For US Only).
DOBIE, Kenneth, W. [GB/US]; (US) (For US Only)
Inventors: BHANOT, Sanjay; (US).
DOBIE, Kenneth, W.; (US)
Agent: CALDWELL, John, W.; Woodcock Washburn LLP, One Liberty Place - 46th Floor, Philadelphia, PA 19103 (US)
Priority Data:
10/188,777 02.07.2002 US
Title (EN) ANTISENSE MODULATION OF INSULIN-LIKE GROWTH FACTOR 2 EXPRESSION
(FR) MODULATION ANTISENS DE L'EXPRESSION DU FACTEUR DE CROISSANCE DE TYPE INSULINE DE TYPE 2
Abstract: front page image
(EN)Antisense compounds, compositions and methods are provided for modulating the expression of insulin-like growth factor 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding insulin-like growth factor 2. Methods of using these compounds for modulation of insulin-like growth factor 2 expression and for treatment of diseases associated with expression of insulin-like growth factor 2 are provided.
(FR)Cette invention concerne des composés antisens, des compositions et des méthodes permettant de moduler l'expression du facteur de croissance de type insuline de type 2. Les compositions comprennent des composés antisens, en particulier des oligonucléotides antisens, ciblés sur des acides nucléiques qui codent pour le facteur de croissance de type insuline de type 2. L'invention concerne également des méthodes d'utilisation de ces composés pour la modulation de l'expression du facteur de croissance de type insuline de type 2 et pour le traitement de maladie associées à l'expression dudit facteur de croissance.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)